Navigation Links
ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012
Date:2/28/2012

SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the fourth quarter and full year ended December 31, 2011 on March 13, 2012. Management will host a conference call to discuss the results at 08:00AM New York Time on March 13, 2012 (08:00PM Beijing Time on March 13, 2012).

Conference Call

Mr. Michael Xin Hui, founder and Chief Executive Officer; Mr. William Dai, Chief Financial Officer; and Ms. Lan Xie, Vice President of Finance and Investor Relations, will discuss the results and take questions following the prepared remarks.

Dial-in details for the live conference call are as follows:

International: +1-718-354-1231
United States: +1-866-519-4004
United Kingdom: 080-8234-6646
Hong Kong: +852-2475-0994

Passcode: SHP

A live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from March 13, 2012, 11:00AM U.S. Eastern Time to March 20, 2012, 11:59PM U.S. Eastern Time. The dial-in details for the replay are as follows:

International: +61-2-8235-5000
Passcode: 57079920

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, please contact: 

ShangPharma
Ms. Lan Xie
Vice President of Finance and Investor Relations
Email: ir@shangpharma.com

Brunswick Group
Josh Gartner
Email: shangpharma@brunswickgroup.com
Phone: 86-10-5960-8600

 


'/>"/>
SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma to Present at Cowens 32nd Annual Health Care Conference
2. ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui
3. ShangPharma Announces Opening of New Facility to Support Lillys Pipeline
4. ShangPharma to Attend Two Upcoming Investor Conferences
5. ShangPharma Announces Third Quarter 2011 Results
6. ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River
7. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
8. ShangPharma Corporation Announces Resignation of a Director
9. ShangPharma Corporation to Hold 2011 Annual General Meeting on October 14, 2011
10. ShangPharma Announces Up to $10 Million Share Repurchase Program
11. ShangPharmas Biologics Division Announces Accelerated Achievement of Milestones for Two Multi-Stage Projects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):